FDA approves Rexulti to treat schizophrenia and as an add‐on to an antidepressant to treat major depressive disorder

On July 10, the U.S. Food and Drug Administration approved Rexulti (brexpiprazole) tablets to treat adults with schizophrenia and as an add‐on treatment to an antidepressant medication to treat adults with major depressive disorder (MDD).

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcpu.30069

Source: The Brown University Child and Adolescent Psychopharmacology Update - August 25, 2015 Category: Psychiatry Tags: From the FDA Source Type: research

More News: Children | Depression | Food and Drug Administration (FDA) | Psychiatry | Schizophrenia